Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice

Clinical and Experimental Immunology

Volumn 170, Issue 2, 2012, Pages 156-166

  Wang, H W ^a   Yang, W ^a   Lu, J Y ^a   Tian, G ^b   Li, F ^a   Wang, X H ^a   Kang, J R ^a   Yang, Y ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Dendritic cells; Fms like tyrosine kinase 3 (Flt3) ligand; Immunoparalysis; Lung injury; Multiple organ dysfunction syndrome

Indexed keywords

CD11B ANTIGEN; CD135 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 12P70; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SERUM ALBUMIN; SODIUM CHLORIDE; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; DENDRITIC CELL; HISTOPATHOLOGY; IMMUNOPARALYSIS; IMMUNOPATHOLOGY; IN VIVO STUDY; LUNG FUNCTION; LUNG INJURY; MORTALITY; MOUSE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIGENS, CD; BODY WEIGHT; DENDRITIC CELLS; FMS-LIKE TYROSINE KINASE 3; INTERLEUKIN-10; INTERLEUKIN-12; LIGANDS; LUNG; LUNG INJURY; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MULTIPLE ORGAN FAILURE; SURVIVAL RATE; ZYMOSAN;

EID: 84867216683     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04641.x     Document Type: Article

References (36)

1. Barie PS, Hydo LJ, Shou J etal. Decreasing magnitude of multiple organ dysfunction syndrome despite increasingly severe critical surgical illness: a 17-year longitudinal study. J Trauma 2008; 65:1227-35.
2. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680-7.
3. Angus DC, Linde WT, Lidicker J etal. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
4. Monneret G, Debard AL, Venet F etal. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003; 31:2068-71.
5. Perl M, Chung CS, Garber M etal. Contribution of anti-inflammatory/immune suppressive processes to the pathology of sepsis. Front Biosci 2006; 11:272-99.
6. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34:1084-93.
7. Julie A, Lorraine B, Gordon R. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27:365-76.
8. Hardaway RM. A brief overview of acute respiratory distress syndrome. World J Surg 2006; 30:1829-34.
9. Salvatore C, Tiziana G, Emanuela M etal. Fumonisin B1 reduces the development of multiple organ failure induced by zymosan in mice. Shock 2009; 31:170-7.
10. Davidson WJ, Dorscheid D, Spragg R etal. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 2006; 10:R41.
11. Joffre O, Nolte MA, Spirri R etal. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227:234-47.
12. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106:259-62.
13. Fujita S, Seino K, Sato K etal. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood 2006; 107:3656-64.
14. Hotchkiss RS, Swanson PE, Freeman BD etal. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27:1230-51.
15. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6:813-22.
16. Benjamim CF, Lundy SK, Lukacs NW etal. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 2005; 10:3588-95.
17. Tinsley KW, Grayson MH, Swanson PE etal. Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol 2003; 171:909-14.
18. Flohe SB, Agrawal H, Schmitz D etal. Dendritic cells during polymicrobial sepsis rapidly mature but fail to initiate a protective Th1-type immune response. J Leukoc Biol 2006; 79:473-81.
19. Kawasaki T, Hubbard WJ, Choudhry MA etal. Trauma-hemorrhage induces depressed splenic dendritic cell functions in mice. J Immunol 2006; 177:4514-20.
20. Lyman SD, James L, Vanden BT etal. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor. A proliferative factor for primitive hematopoietic cells. Cell 1993; 75:1157-67.
21. Toby PH, Coates SM, Barratt B etal. Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand. Blood 2003; 102:2513-21.
22. Drakes ML, Subbotin VM, Thomson AW. In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J Immunol 1997; 159:4268-78.
23. Marasovsky E, Daro E, Roux E etal. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96:878-84.
24. Teleshova N, Jones J, Kenney J etal. Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells. J Leukoc Biol 2004; 75:1102-10.
25. Masten BJ, Gwyneth K, Kusewitt DF etal. Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice. J Immunol 2004; 172:4077-83.
26. Goris RJ, Boekholtz WK, van Bebber IP etal. Multiple organ failure and sepsis without bacteria: an experimental model. Arch Surg 1986; 121:897-901.
27. Onai N, Obata-Onai A, Tussiwand R etal. Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J Exp Med 2006; 203:227-38.
28. Pulendran JL, Smith MJ, Schoenborn M. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant. J Exp Med 1998; 188:2075-82.
29. Wysocka M, Montaner LJ, Karp CL. Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis. J Immunol 2005; 174:7398-402.
30. Patrick GH. Antigen presentation in the lung. Am J Respir Crit Care Med 2000; 162:S151-6.
31. Toliver-Kinsky TE, Cui W, Murphy ED. Enhancement of dendritic cell production by Fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. J Immunol 2005; 174:404-10.
32. Bohannon J, Cui W, Cox R etal. Prophylactic treatment with Fms-like tyrosine Kinase-3 ligand after burn injury enhances global immune responses to infection. J Immunol 2008; 180:3038-48.
33. Cuzzocrea S, Genovese T, Mazzon E etal. Fumonisin B1 reduces the development of multiple organ failure induced by zymosan in mice. Shock 2009; 32:170-7.
34. Tiziana G, Rosanna DP, Paolo C. Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice. Crit Care Med 2004; 32:1365-74.
35. Wooland DW, Hodge LM, Simecka JW etal. The upper and lower respiratory tracts differ in their requirement of IFN-γ and IL-4 in controlling respiratory mycoplasma infection and disease. J Immunol 2004; 172:6875-83.
36. Steinman RC. Some active areas of DC research and their medical potential. Eur J Immunol 2010; 40:2088-8.